• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March

    4/15/24 2:30:37 PM ET
    $LGVN
    $MRNS
    $NMRA
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LGVN alert in real time by email

    U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday.

    The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also fell, dropping, 1.14% to 5,065.04.

    Check This Out: Best Buy, Box And 2 Other Stocks Insiders Are Selling

     

    Leading and Lagging Sectors

     

    Health care shares rose by 0.01% on Friday.

    In trading on Friday, information technology shares fell by 1.8%.

     

    Top Headline

     

    U.S. retail sales increased 0.7% month-over-month in March following a revised 0.9% rise in February.

     

    Equities Trading UP

     

    Soligenix, Inc. (NASDAQ:SNGX) shares shot up 34% to $0.5197 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA.

    Shares of Longeveron Inc. (NASDAQ:LGVN) got a boost, surging 58% to $2.6750 following insider buys from multiple company executives.

    Snap One Holdings Corp. (NASDAQ:SNPO) shares were also up, gaining 30% to $10.60 after the company announced that it will be acquired by Resideo Technologies.

     

    Equities Trading DOWN

     

    Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) shares dropped 81% to $1.4250 after the company provided an update on the Phase 3 RAISE trial and reported preliminary first-quarter financial results.

    Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) were down 11% to $12.02 after the FDA placed a clinical hold on the company's Phase 1 NMRA-266 study.

    Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was down, falling 10% to $42.73 after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.

    Also Check This Out: Wall Street's Most Accurate Analysts' Views On 3 Tech Stocks With Over 4% Dividend Yields

     

    Commodities

     

    In commodity news, oil traded down 0.6% to $85.17 while gold traded up 0.3% at $2,381.50.

    Silver traded up 1.6% to $28.795 on Friday, while copper rose 2.3% to $4.3575.

     

    Euro zone

     

    European shares closed mostly higher today. The eurozone’s STOXX 600 rose 0.13%, London’s FTSE 100 fell 0.38% while Spain’s IBEX 35 Index rose 0.01% The German DAX gained 0.54% French CAC 40 climbed 0.43% while Italy’s FTSE MIB Index jumped 0.56%.

    Industrial production in the eurozone increased by 0.8% month-over-month in February.

     

    Asia Pacific Markets

     

    Asian markets closed mostly lower on Monday, with Japan’s Nikkei 225 falling 0.74%, Hong Kong’s Hang Seng Index dropping 0.72%, China’s Shanghai Composite gaining 1.26% and India’s S&P BSE Sensex dipping 1.14%.

    Indian merchandise trade deficit shrank to $15.6 billion in March versus a year-ago gap of $18.1 billion, while wholesale prices rose by 0.53% year-over-year in March versus a 0.20% gain in the prior month.

     

    Economics

     

    The NY Empire State Manufacturing Index climbed to -14.3 in April versus prior month’s reading of -20.9.

    Retail sales increased 0.7% month-over-month in March following a revised 0.9% rise in February.

    The NAHB/Wells Fargo Housing Market Index in came in unchanged at 51.0 in April.

    Total business inventories increased by 0.4% month-over-month in February, versus market expectations of a 0.3% rise.

    Now Read This: Bitcoin Surpasses $66,000; Core Emerges As Top Gainer

     

    Get the next $LGVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LGVN
    $MRNS
    $NMRA
    $RARE

    CompanyDatePrice TargetRatingAnalyst
    Neumora Therapeutics Inc.
    $NMRA
    1/12/2026$8.00Outperform
    Leerink Partners
    Neumora Therapeutics Inc.
    $NMRA
    12/1/2025$7.00Sector Perform → Outperform
    RBC Capital Mkts
    Neumora Therapeutics Inc.
    $NMRA
    10/27/2025$14.00Neutral → Buy
    Guggenheim
    Ultragenyx Pharmaceutical Inc.
    $RARE
    10/20/2025$65.00Overweight
    Wells Fargo
    Neumora Therapeutics Inc.
    $NMRA
    9/16/2025Neutral → Underweight
    Analyst
    Ultragenyx Pharmaceutical Inc.
    $RARE
    7/28/2025$80.00Buy
    H.C. Wainwright
    Ultragenyx Pharmaceutical Inc.
    $RARE
    5/28/2025Outperform
    William Blair
    Neumora Therapeutics Inc.
    $NMRA
    4/2/2025$1.00Buy → Underperform
    BofA Securities
    More analyst ratings

    $LGVN
    $MRNS
    $NMRA
    $RARE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Horn Howard sold $72,117 worth of shares (3,061 units at $23.56), decreasing direct ownership by 3% to 88,935 units (SEC Form 4)

    4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

    2/3/26 12:00:41 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Milligan Michael Lee

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    1/9/26 4:20:47 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Officer Aurora Daljit Singh

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    1/9/26 4:19:28 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LGVN
    $MRNS
    $NMRA
    $RARE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Soligenix Details Recent Progress and Upcoming Milestones

    PRINCETON, N.J., Feb. 12, 2026 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber.  The content of this letter is provided below. Dear Friends and Shareholders, I would like to start by thanking you for your continued support, and by wishing you and your families a Happy New Year. With 2026 being an imp

    2/12/26 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update

    NOVATO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, February 12, 2026, to discuss its financial results and corporate update for the quarter and the year ending December 31, 2025. The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months. About Ultragenyx Pharmaceutical Inc.Ultragenyx

    2/5/26 4:05:00 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program

    The Mikaela Naylon Give Kids a Chance Act reauthorizes the Pediatric Priority Review Voucher (PPRV) Program and extends eligibility for medicines achieving U.S. FDA approval before September 2029The Pediatric Priority Review Voucher program encourages the development of treatments for rare pediatric diseasesU.S. FDA has awarded Longeveron's laromestrocel Hypoplastic Left Heart Syndrome (HLHS) program Rare Pediatric Disease designation, Orphan Drug designation, and Fast Track designationWith the extension of the PPRV Program, Longeveron may be granted a Priority Review Voucher if laromestrocel's Biological License Application (BLA) is approved by the FDA before September 2029 MIAMI, Feb. 05

    2/5/26 9:15:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    $MRNS
    $NMRA
    $RARE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Neumora Therapeutics with a new price target

    Leerink Partners initiated coverage of Neumora Therapeutics with a rating of Outperform and set a new price target of $8.00

    1/12/26 8:18:29 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neumora Therapeutics upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Neumora Therapeutics from Sector Perform to Outperform and set a new price target of $7.00

    12/1/25 8:13:43 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neumora Therapeutics upgraded by Guggenheim with a new price target

    Guggenheim upgraded Neumora Therapeutics from Neutral to Buy and set a new price target of $14.00

    10/27/25 8:50:37 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LGVN
    $MRNS
    $NMRA
    $RARE
    SEC Filings

    View All

    Neumora Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)

    2/11/26 7:00:26 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Ultragenyx Pharmaceutical Inc.

    SCHEDULE 13G/A - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

    2/5/26 1:40:12 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ultragenyx Pharmaceutical Inc. filed SEC Form 8-K: Other Events

    8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

    2/3/26 8:15:25 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    $MRNS
    $NMRA
    $RARE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Burow Kristina bought $4,999,977 worth of shares (1,915,700 units at $2.61) (SEC Form 4)

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    10/29/25 7:22:24 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Arch Venture Partners Xii, Llc bought $4,999,977 worth of shares (1,915,700 units at $2.61) (SEC Form 4)

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    10/29/25 7:21:13 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Arch Venture Partners X, Llc bought $4,999,977 worth of shares (1,915,700 units at $2.61) (SEC Form 4)

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    10/29/25 7:19:14 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LGVN
    $MRNS
    $NMRA
    $RARE
    Leadership Updates

    Live Leadership Updates

    View All

    George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors

    MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that George Paletta, Jr., MD, MBA, has been elected to the Longeveron Board of Directors. Dr. Paletta is a nationally and internationally recognized orthopedic surgeon and the head team doctor for the St. Louis Cardinals. Dr. Paletta is a developer of ambulatory surgical centers (ASCs), and has participated in the selling of two ASCs with deal values totaling almost $1 billion. "I am delighted to welcome George, and his tremendous experience as a physician, inv

    10/1/25 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

    NOVATO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced the appointment of Eric Olson as chief business officer (CBO) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg. Mr. Olson will be responsible for leading the company's business development, corporate development and alliance management functions. "We thank Tom for his 14 years of impactful contributions to Ultragenyx, including transformative business deals that helped build the largest clinical pipeline in rare disease; expanded our reach to patients with fatty acid oxidation diseases, X-linked hypophosphatemia, o

    9/30/25 4:05:00 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

    Contributing Broad Business and Government Affairs Expertise and Network PRINCETON, N.J., Sept. 23, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of Tomas J. Philipson, PhD as a Strategic Advisor. Dr. Philipson is considered an expert in United States (U.S.) economic policy, particularly health care policy, and frequently appears on major media outlets, including F

    9/23/25 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    $MRNS
    $NMRA
    $RARE
    Financials

    Live finance-specific insights

    View All

    Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update

    NOVATO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, February 12, 2026, to discuss its financial results and corporate update for the quarter and the year ending December 31, 2025. The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months. About Ultragenyx Pharmaceutical Inc.Ultragenyx

    2/5/26 4:05:00 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on Resideo Technologies, Inc. (NYSE: REZI)

    NOTE TO EDITORS: The Following Is an Investment Opinion Issued by Spruce Point Capital Management Identifies Long-Term Failures By Management To Achieve Organic Growth, Margin or Cash Flow Targets or To Rectify Operational Challenges And Complexities With A Fully Implemented ERP System Expresses Concerns With The Revolving Door At the CFO and CAO Roles, While Financial Reporting and Accounting For Recent M&A Transactions, Notably First Alert And Snap One Holdings, Appears Problematic Believes That Dubious Recurring Restructuring Add-Backs and Questionable Tax Maneuvers At Foreign Entities Where Deloitte Was Replaced As Auditor May Be Inflating Financial Results Calls on the Audit Co

    1/27/26 9:00:00 AM ET
    $NWL
    $REZI
    $SNPO
    Plastic Products
    Industrials
    Wholesale Distributors
    Electrical Products

    Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation

    NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect  NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified population with elevated anxiety NMRA-511 demonstrated a favorable tolerability and safety profile Neumora plans to evaluate higher doses of NMRA-511 via initiation of a multiple ascending dose expansion cohort in 2026 Company to host conference call today at 8:00 am ET WATERTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms

    1/5/26 6:30:00 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LGVN
    $MRNS
    $NMRA
    $RARE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Neumora Therapeutics Inc.

    SC 13D/A - Neumora Therapeutics, Inc. (0001885522) (Subject)

    11/22/24 5:33:43 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

    SC 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    11/15/24 10:35:20 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Marinus Pharmaceuticals Inc.

    SC 13G - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    11/14/24 6:39:04 PM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care